Wedbush Raises United Therapeutics Price Target to $141.00 (UTHR)
Investment analysts at Wedbush upped their price target on shares of United Therapeutics (NASDAQ:UTHR) to $141.00 in a note issued to investors on Friday. Wedbush’s target price points to a potential upside of 53.78% from the stock’s previous close.
A number of other analysts have also recently weighed in on UTHR. Analysts at Standpoint Research raised their price target on shares of United Therapeutics from $118.00 to $140.00 in a research note on Friday. They now have a “buy” rating on the stock. Separately, analysts at Zacks upgraded shares of United Therapeutics from a “neutral” rating to an “outperform” rating in a research note on Thursday, August 21st. They now have a $112.00 price target on the stock. Finally, analysts at RBC Capital raised their price target on shares of United Therapeutics from $90.00 to $93.00 in a research note on Thursday, July 31st. Five equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $104.87.
In other United Therapeutics news, CFO John Maxim Ferrari sold 10,000 shares of United Therapeutics stock on the open market in a transaction that occurred on Thursday, August 21st. The shares were sold at an average price of $93.75, for a total value of $937,500.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
Shares of United Therapeutics (NASDAQ:UTHR) traded up 26.86% on Friday, hitting $116.32. The stock had a trading volume of 4,158,671 shares. United Therapeutics has a 1-year low of $70.68 and a 1-year high of $116.65. The stock’s 50-day moving average is $91.63 and its 200-day moving average is $95.41. The company has a market cap of $5.498 billion and a price-to-earnings ratio of 17.72.
United Therapeutics (NASDAQ:UTHR) last released its earnings data on Tuesday, July 29th. The company reported $2.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.75 by $0.82. The company had revenue of $322.80 million for the quarter, compared to the consensus estimate of $308.04 million. During the same quarter in the previous year, the company posted $1.52 earnings per share. The company’s revenue for the quarter was up 15.0% on a year-over-year basis. Analysts expect that United Therapeutics will post $8.55 EPS for the current fiscal year.
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions.
Receive News & Ratings for United Therapeutics Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Co and related companies with Analyst Ratings Network's FREE daily email newsletter.